MIMatthew A. Inlay

Matthew A. Inlay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew A. Inlay has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Alborz Karimzadeh

    Sue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA

    4 shared publications
  • Connie Chao

    Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, United States

    4 shared publications
  • Cuiwen Zhou

    Department of Molecular Biology and Biochemistry, University of California, Irvine

    4 shared publications
  • Erika S. Varady

    Department of Molecular Biology and Biochemistry, University of California, Irvine

    4 shared publications
  • Pauline U. Nguyen

    Sue and Bill Gross Stem Cell Research Center, University of California, Irvine

    4 shared publications
  • Thomas Serwold

    Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, United States

    4 shared publications

Latest Publications

  • Open Access

    Short term ex vivo graft conditioning with venetoclax, fluticasone propionate, and IL-2 reduces graft versus host disease in mouse allogeneic hematopoietic cell transplantation

    by L. Angel Ayala, Alizeh Ahmedani, Cuiwen Zhou, Gabriella L. Hisoire, Alexii Villamar, Michelle Baez, Nathalia Onofre, Chanel De Smet, Pauline U. Nguyen, Vanessa M. Scarfone, et al.

    Hematopoietic cell transplantation is a curative therapy for certain hematologic malignancies but is limited in use due to post-transplant complications such as graft-versus-host disease (GVHD), wherein donor cells mount an immune response against host tissues. GVHD is a major cause of post-transplant mortality, inspiring the development of prophylactic strategies to reduce GVHD severity. However, these involve administration of cytotoxic or immunosuppressive compounds into patients, increasing adverse side effects. To address this issue, we have developed a strategy to reduce GVHD through ex vivo graft conditioning. Previously we demonstrated that pretreatment of mouse grafts with a single compound, fluticasone propionate, dramatically reduced GVHD symptoms after allogeneic transplantation. Here, we condition grafts in a combination of fluticasone propionate, venetoclax, and IL-2 for 6 hours ex vivo prior to transplantation. We demonstrate that the preconditioning process increases the frequency of tolerogenic regulatory T cells pre- and post-transplant. Recipient mice receiving conditioned cells display reduced GVHD severity and increased overall survival in both fully mismatched and haploidentical models. This study highlights an alternative strategy to GVHD prophylaxis which reduces reliance on the administration of toxic compounds.

  • Flow Cytometry Analysis of Graft Conditioning on the T-Cell Response in Graft-Versus-Host Disease Following Murine Allogeneic Transplantation

    by L. Angel Ayala, Erika S. Varady, Cuiwen Zhou, Xiyu Chen, Abigail Valdovinos, Alizeh H. Ahmedani, Gabriella L. Hisoire, Pauline U. Nguyen, Vanessa M. Scarfone, Matthew A. Inlay

    Acute graft-versus-host disease (aGVHD) remains a common life-threatening complication associated with allogeneic hematopoietic cell transplantation (allo-HCT) and is a major contributor to posttransplant mortality and morbidity. In allo-HCT, allogeneic T cells recognize host tissues as foreign and mount an immune response, causing inflammation and tissue damage. Traditionally, GVHD patients receive a regimen of immunosuppressive glucocorticoids after the onset of symptoms; however, many groups are developing prophylactic strategies due to the consequences associated with long-term glucocorticoid administration. Despite the advances made to mitigate GVHD, it remains a risk following allo-HCT; thus, new therapies are required to improve the safety of this therapy. Here, we use a prophylactic strategy that leverages graft manipulation as a way to induce tolerance upon transplantation. This chapter focuses on the techniques involved in conditioning donor cells, transplantation, and posttransplantation analysis of immune cells in a murine major histocompatibility complex (MHC) mismatched model of GVHD.


  • Mass Cytometry Immunophenotyping of Graft-Conditioned Cells Following Major Histocompatibility Complex Mismatched Murine Allograft

    by L. Angel Ayala, Pauline U. Nguyen, Cuiwen Zhou, Gabriella L. Hisoire, Alizeh H. Ahmedani, Xiyu Chen, Ankita Daud, Abigail Valdovinos, Erika S. Varady, Matthew A. Inlay, et al.

    Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for a variety of blood disorders but primarily reserved for blood cancer patients due to the life-threatening risk of acute graft-versus-host disease (aGVHD). Development of aGVHD is driven by alloreactive T cells that recognize the recipient's tissues as foreign and initiate a robust immune response causing severe tissue damage of the skin, liver, and gut. While methods to reduce aGVHD incidence and severity exist including posttransplant cyclophosphamide, relapse rates and transplantation-related mortality remain. We previously published a study using graft conditioning with glucocorticoids as a strategy to modify the immune repertoire in the donor grafts prior to transplantation to reduce aGVHD. Here, we describe a protocol to characterize the T-cell response in recipient mice given transplantation of graft-conditioned allogeneic donor cells via mass cytometry. Mass cytometry is a technology that uses heavy metal tags in place of fluorochromes to allow high-dimensional flow cytometric analysis. In this protocol, we include an antibody panel of 39 different antibodies conjugated to 41 different heavy metal tags that have been validated and titrated for barcoding and immunophenotyping by lineage markers, activation markers, cytokine secretion, and transcription factors. This chapter details the graft conditioning, transplantation, processing, barcoding, staining, and mass cytometric analysis of immune cells following murine allo-HCT.


  • Open Access

    Graft conditioning with fluticasone propionate reduces graft‐versus‐host disease upon allogeneic hematopoietic cell transplantation in mice

    by Erika S Varady, L Angel Ayala, Pauline U Nguyen, Vanessa M Scarfone, Alborz Karimzadeh, Cuiwen Zhou, Xiyu Chen, Scott A Greilach, Craig M Walsh, Matthew A Inlay

    Hematopoietic cell transplantation (HCT) treats many blood conditions but remains underused due to complications such as graft‐versus‐host disease (GvHD). In GvHD, donor immune cells attack the patient, requiring powerful immunosuppressive drugs like glucocorticoids (GCs) to prevent death. In this study, we tested the hypothesis that donor cell conditioning with the glucocorticoid fluticasone propionate (FLU) prior to transplantation could increase hematopoietic stem cell (HSC) engraftment and reduce GvHD. Murine HSCs treated with FLU had increased HSC engraftment and reduced severity and incidence of GvHD after transplantation into allogeneic hosts. While most T cells died upon FLU treatment, donor T cells repopulated in the hosts and appeared less inflammatory and alloreactive. Regulatory T cells (Tregs) are immunomodulatory and survived FLU treatment, resulting in an increased ratio of Tregs to conventional T cells. Our results implicate an important role for Tregs in maintaining allogeneic tolerance in FLU‐treated grafts and suggest a therapeutic strategy of pre‐treating donor cells (and not the patients directly) with GCs to simultaneously enhance engraftment and reduce GvHD upon allogeneic HCT.


  • MAC2 is a long‐lasting marker of peripheral cell infiltrates into the mouse CNS after bone marrow transplantation and coronavirus infection

    by Lindsay A. Hohsfield, Kate I. Tsourmas, Yasamine Ghorbanian, Amber R. Syage, Sung Jin Kim, Yuting Cheng, Susana Furman, Matthew A. Inlay, Thomas E. Lane, Kim N. Green

    Microglia are the primary resident myeloid cells of the brain responsible for maintaining homeostasis and protecting the central nervous system (CNS) from damage and infection. Monocytes and monocyte‐derived macrophages arising from the periphery have also been implicated in CNS pathologies, however, distinguishing between different myeloid cell populations in the CNS has been difficult. Here, we set out to develop a reliable histological marker that can assess distinct myeloid cell heterogeneity and functional contributions, particularly in the context of disease and/or neuroinflammation. scRNAseq from brains of mice infected with the neurotropic JHM strain of the mouse hepatitis virus (JHMV), a mouse coronavirus, revealed that Lgals3 is highly upregulated in monocyte and macrophage populations, but not in microglia. Subsequent immunostaining for galectin‐3 (encoded by Lgals3), also referred to as MAC2, highlighted the high expression levels of MAC2 protein in infiltrating myeloid cells in JHMV‐infected and bone marrow (BM) chimeric mice, in stark contrast to microglia, which expressed little to no staining in these models. Expression of MAC2 was found even 6–10 months following BM‐derived cell infiltration into the CNS. We also demonstrate that MAC2 is not a specific label for plaque‐associated microglia in the 5xFAD mouse model, but only appears in a distinct subset of these cells in the presence of JHMV infection or during aging. Our data suggest that MAC2 can serve as a reliable and long‐lasting histological marker for monocyte/macrophages in the brain, identifying an accessible approach to distinguishing resident microglia from infiltrating cells in the CNS under certain conditions.


  • Open Access

    Absence of CD11a Expression Identifies Embryonic Hematopoietic Stem Cell Precursors via Competitive Neonatal Transplantation Assay

    by Alborz Karimzadeh, Erika S. Varady, Vanessa M. Scarfone, Connie Chao, Karin Grathwohl, Pauline U. Nguyen, Yasamine Ghorbanian, Irving L. Weissman, Thomas Serwold, Matthew A. Inlay

    Hematopoietic stem cells (HSCs) are defined by their self-renewal, multipotency, and bone marrow (BM) engraftment abilities. How HSCs emerge during embryonic development remains unclear, but are thought to arise from hemogenic endothelium through an intermediate precursor called “pre-HSCs.” Pre-HSCs have self-renewal and multipotent activity, but lack BM engraftability. They can be identified functionally by transplantation into neonatal recipients, or byin vitroco-culture with cytokines and stroma followed by transplantation into adult recipients. While pre-HSCs express markers such as Kit and CD144, a precise surface marker identity for pre-HSCs has remained elusive due to the fluctuating expression of common HSC markers during embryonic development. We have previously determined that the lack of CD11a expression distinguishes HSCs in adults as well as multipotent progenitors in the embryo. Here, we use a neonatal transplantation assay to identify pre-HSC populations in the mouse embryo. We establish CD11a as a critical marker for the identification and enrichment of pre-HSCs in day 10.5 and 11.5 mouse embryos. Our proposed pre-HSC population, termed “11a- eKLS” (CD11a- Ter119- CD43+ Kit+ Sca1+ CD144+), contains allin vivolong-term engrafting embryonic progenitors. This population also displays a cell-cycle status expected of embryonic HSC precursors. Furthermore, we identify the neonatal liver as the likely source of signals that can mature pre-HSCs into BM-engraftable HSCs.


  • Open Access

    Author Correction: Gene correction for SCID-X1 in long-term hematopoietic stem cells

    by Mara Pavel-Dinu, Volker Wiebking, Beruh T. Dejene, Waracharee Srifa, Sruthi Mantri, Carmencita E. Nicolas, Ciaran Lee, Gang Bao, Eric J. Kildebeck, Niraj Punjya, et al.

    The original version of this Article omitted the following from the Acknowledgements: “G.B. acknowledges the support from the Cancer Prevention and Research Institute of Texas (RR140081 and RR170721).”This has now been corrected in both the PDF and HTML versions of the Article.


  • Open Access

    Induction of Mesoderm and Neural Crest-Derived Pericytes from Human Pluripotent Stem Cells to Study Blood-Brain Barrier Interactions

    by Tannaz Faal, Duc T.T. Phan, Hayk Davtyan, Vanessa M. Scarfone, Erika Varady, Mathew Blurton-Jones, Christopher C.W. Hughes, Matthew A. Inlay


  • CD11a expression distinguishes infiltrating myeloid cells from plaque‐associated microglia in Alzheimer's disease

    by Ankita K. Shukla, Laura L. McIntyre, Samuel E. Marsh, Christine A. Schneider, Evelyn M. Hoover, Craig M. Walsh, Melissa B. Lodoen, Mathew Blurton‐Jones, Matthew A. Inlay

    Alzheimer's disease (AD) is the leading cause of age‐related neurodegeneration and is characterized neuropathologically by the accumulation of insoluble beta‐amyloid (Aβ) peptides. In AD brains, plaque‐associated myeloid (PAM) cells cluster around Aβ plaques but fail to effectively clear Aβ by phagocytosis. PAM cells were originally thought to be brain‐resident microglia. However, several studies have also suggested that Aβ‐induced inflammation causes peripheral monocytes to enter the otherwise immune‐privileged brain. The relationship between AD progression and inflammation in the brain remains ambiguous because microglia and monocyte‐derived macrophages are extremely difficult to distinguish from one another in an inflamed brain. Whether PAM cells are microglia, peripheral macrophages, or a mixture of both remains unclear. CD11a is a component of the β2 integrin LFA1. We have determined that CD11a is highly expressed on peripheral immune cells, including macrophages, but is not expressed by mouse microglia. These expression patterns remain consistent in LPS‐treated inflamed mice, as well as in two mouse models of AD. Thus, CD11a can be used as a marker to distinguish murine microglia from infiltrating peripheral immune cells. Using CD11a, we show that PAM cells in AD transgenic brains are comprised entirely of microglia. We also demonstrate a novel fluorescence‐assisted quantification technique (FAQT), which reveals a significant increase in T lymphocytes, especially in the brains of female AD mice. Our findings support the notion that microglia are the lead myeloid players in AD and that rejuvenating their phagocytic potential may be an important therapeutic strategy.


  • Open Access

    Gene Correction for SCID-X1 in Long-Term Hematopoietic Stem Cells

    by Mara Pavel-Dinu, Volker Wiebking, Beruh T. Dejene, Waracharee Srifa, Sruthi Mantri, Carmencita E. Nicolas, Ciaran Lee, Gang Bao, Eric J. Kildebeck, Niraj Punjya, et al.

    Gene correction in human long-term hematopoietic stem cells (LT-HSCs) could be an effective therapy for monogenic diseases of the blood and immune system. High frequencies of reproducible targeted integration of a wild-type cDNA into the endogenous start codon of a gene in LT-HSCs could provide a robust genome editing approach to cure genetic diseases in which patients have different mutations throughout the gene. We describe a clinically relevant method for correcting X-linked severe combined immunodeficiency (SCID-X1). By using a highly specific and active CRISPR/Cas9-AAV6 based strategy and selection-free approach, we achieve up to 20% genome integration frequencies in LT-HSCs of a full-length IL2RG cDNA at the endogenous start site as demonstrated by serial transplantation and analysis of genome edited human cells eight months following initial transplantation. In addition to high frequencies of functional gene correction in LT-HSCs we observed no evidence of abnormal hematopoiesis following transplantation, a functional measure of the lack of genotoxicity. Deep analysis of potential off-target activity detected two sites with low frequency (+ HSPCs from six SCID-X1 patients and demonstrate rescue of lymphopoietic defect of patient derived cells both in vitro and in vivo. In sum, our study provides specificity, toxicity and efficacy data supportive of clinical development of genome editing to treat SCID-Xl.